About Velvet Bean
Mucuna pruriens (velvet bean) is a tropical legume whose seeds contain natural L-DOPA (levodopa), the direct precursor to dopamine. Standardized extracts typically deliver 15–50% L-DOPA. Strongest clinical evidence is in Parkinson's disease as a levodopa-replacement: Katzenschlager 2004 (acute crossover, n=8 PD patients) used 15 g and 30 g raw seed powder and showed faster onset and longer motor response than synthetic levodopa/carbidopa, without increased dyskinesia despite higher peak L-DOPA exposure; Cilia 2017 (acute crossover, n=18) compared seed powder to levodopa + DDCI with comparable motor efficacy and reduced dyskinesias; Cilia 2018 (16-week pilot, n=14) is the only chronic-dosing PD trial. For male fertility, Shukla 2009 (RCT, n=75 infertile men, 5 g/day seed powder, 3 months) reported improved sperm parameters and testosterone — note this and Shukla 2010 are a single Lucknow cohort, not independent replications. Evidence in healthy adults for mood, libido, or cognition is mechanistic only — no RCT support. L-DOPA content varies 2–7x between unstandardized seed products and degrades in storage, so only standardized extracts deliver predictable doses. Contains L-DOPA — should not be combined with synthetic levodopa, MAOIs, antipsychotics, or other dopaminergic medications without medical supervision. Not recommended in pregnancy, melanoma, or psychotic disorders. No established RDA/UL.
What Velvet Bean supports
- Standardized extracts deliver L-DOPA — clinical evidence is in Parkinson's disease only, not healthy adults
- RCT evidence for sperm parameters and testosterone in infertile men only — no benefit shown in healthy men
How much Velvet Bean to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
200–600
mg
Standardized seed extract (typically 15–20% L-DOPA); 200–600 mg/day covers the supplement-context range used in commercial products. Whole seed powder doses studied in Parkinson's research are far higher (15–30 g delivering ~1.5–5 g L-DOPA) and fall outside the supplement scoring window — those are medical-supervision territory.
Clinical evidence
Moderate clinical evidence. Moderate evidence in Parkinson's disease (small acute crossovers + 1 16-week pilot, total n<50). Low evidence for supplement-context claims (fertility = single-center Lucknow cohort; no RCTs in healthy adults for mood, libido, or cognition). Active compound L-DOPA carries real drug-interaction risk.
Examine.com